| 產品編號 | bs-2984R-FITC |
| 英文名稱 | Rabbit Anti-phospho-PLB(Ser16)/FITC Conjugated antibody |
| 中文名稱 | FITC標記的磷酸化心臟磷蛋白抗體 |
| 別 名 | Phospholamban (phospho S16); p-Phospholamban (phospho S16); p-PLB(S16); Cardiac phospholamban; CMD1P; PLB; PLN; PPLA_HUMAN. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 產品類型 | 磷酸化抗體 |
| 研究領域 | 心血管 免疫學 信號轉導 轉錄調節因子 通道蛋白 細胞表面分子 線粒體 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, Dog, Pig, Cow, Rabbit, ) |
| 產品應用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 5.7kDa |
| 細胞定位 | 細胞膜 線粒體 |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human Cardiac phospholamban around the phosphorylation site of Ser16 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: Defects in PLN are the cause of cardiomyopathy dilated type 1P (CMD1P) . Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. Defects in PLN are the cause of cardiomyopathy familial hypertrophic type 18 (CMH18) . CMH18 is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. Function: Phospholamban has been postulated to regulate the activity of the calcium pump of cardiac sarcoplasmic reticulum. Subunit: Homopentamer. Interacts with HAX1. Subcellular Location: Mitochondrion membrane; Single-pass membrane protein. Sarcoplasmic reticulum. Tissue Specificity: Heart. Post-translational modifications: Phosphorylated at Thr-17 by CaMK2, and in response to beta-adrenergic stimulation. Phosphorylation by DMPK may stimulate sarcoplasmic reticulum calcium uptake in cardiomyocytes. DISEASE: [DISEASE] Defects in PLN are the cause of cardiomyopathy dilated type 1P (CMD1P) [MIM:609909]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. [DISEASE] Defects in PLN are the cause of familial hypertrophic cardiomyopathy type 18 (CMH18) [MIM:613874]. CMH18 is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. Similarity: Belongs to the phospholamban family. Database links: Entrez Gene: 5350 Human Entrez Gene: 18821 Mouse Omim: 172405 Human SwissProt: P26677 Chicken SwissProt: P26678 Human SwissProt: P61014 Mouse SwissProt: P61015 Rabbit Unigene: 170839 Human Unigene: 745010 Human Unigene: 34145 Mouse Unigene: 9740 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
